SPYRE THERAPEUTICS, INC. Other Significant Noncash Transaction, Value of Consideration Given
SPYRE THERAPEUTICS, INC. (SYRE) reported Other Significant Noncash Transaction, Value of Consideration Given of $232.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2018-03-13
- SPYRE THERAPEUTICS, INC. other significant noncash transaction, value of consideration given for the quarter ending 2015-12-31 was -$117.00K.
- SPYRE THERAPEUTICS, INC. other significant noncash transaction, value of consideration given for the quarter ending 2015-09-30 was -$155.00K.
- SPYRE THERAPEUTICS, INC. other significant noncash transaction, value of consideration given for fiscal 2015 was $232.00K.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month |
|---|---|---|---|---|
| 2015-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$272.00K derived: sum of 2 quarters · filed 2018-03-13 | $232.00K 10-K · filed 2018-03-13 | |
| 2015-09-30 | -$155.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $349.00K 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $504.00K 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |